Search

Search


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

106. Magdalen College Acquires 100% of The Oxford Science Park.

Magdalen College Acquires 100% of The Oxford Science Park.04/01/2016Oxford, UK – Magdalen College has completed the acquisition of the 50% stake in The Oxford Science Park joint venture held by M&G Real Estate, to take 100% control of the management and future development of the Park.  The consideration was £18.1m in cash.The Oxford Science Park was established in 1991 as a 50/50 joint venture to deliver high-quality commercial offices and laboratories for science and technol


107. Shire to Combine with Baxalta, Creating the Global Leader in Rare Dise

Shire to Combine with Baxalta, Creating the Global Leader in Rare Diseases11/01/2016Shire plc (LSE: SHP, NASDAQ: SHPG) and Baxalta Incorporated (NYSE: BXLT) today announced that the boards of directors of both companies have reached an agreement under which Shire will combine with Baxalta. Under the agreement, Baxalta shareholders will receive $18.00 in cash and 0.1482 Shire ADS per Baxalta share. Based on Shire’s closing ADS price on January 8, 2016, this implies a total current value of


108. Inivata Completes £31.5 Million ($45M) Series A Fundraising Round

Inivata Completes £31.5 Million ($45M) Series A Fundraising Round26/01/2016Funds to Drive Clinical Development of New Approaches to Improve Cancer Treatment and Outcomes through Liquid BiopsiesInivata Limited, a clinical cancer genomics company employing the precision of circulating tumour DNA (“ctDNA”) analysis to improve personalized healthcare in oncology, today announced the completion of a Series A fundraising of £31.5 Million ($45M). Existing investors Imperial Innova


109. Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration

Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration02/02/2016London, UK, Philadelphia, USA. and Oxford, UK,  – Adaptimmune Therapeutics plc, a leader in the use of T- cell receptor (TCR) engineered T-cell therapy to treat cancer, and GlaxoSmithKline plc today announced that the companies have expanded the terms of their strategic collaboration agreement to accelerate Adaptimmune’s lead clinical cancer program, an affinity enhanced T-cell immunotherapy (GSK3377794) t


110. OxLEP Announces New Chair

OxLEP Announces New Chair 04/03/2016 Oxford, UK – Oxfordshire Local Enterprise Partnership (OxLEP) announces the appointment of Jeremy Long as the new OxLEP Chair.Jeremy Long is Chief Executive of European Business for MTR Corporation, he is succeeding Adrian Shooter who stepped down in October 2014 following the completion of his five year term.OxLEP is the strategic business-led organisation focusing on county wide economic growth; Mr Long outlined his desire to use his experie



Page 22 of 44 ( 219 results in total )
© Catalyst Innovation Portal 2019